Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development
The Pharma Data
DECEMBER 2, 2020
She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).
52 
Let's personalize your content